The gold-standard clinician-administered scale for drug-induced akathisia. Assessment combines objective observation with patient-reported subjective experience.
1
Objective observed movements
Based on observation during the interview
2
Subjective awareness of restlessness
Ask about inner tension or urge to move
3
Subjective distress with restlessness
The degree of discomfort caused by the urge to move
Screening for drug-induced akathisia (DIA) in patients receiving antipsychotics or other dopamine antagonists.
Monitoring response to anti-akathisia treatments (e.g., beta-blockers, benzodiazepines).
Differentiating akathisia from agitation, restless legs syndrome (RLS), or psychotic anxiety.
Routine safety monitoring during dose escalation of D2-receptor blockers.
Patient Populations
The BARS is the gold standard for extrapyramidal symptom (EPS) monitoring in adults. Use caution when interpreting results in patients with severe Parkinsonism or tardive dyskinesia, as motor symptoms may overlap.
Section 2
Formula & Logic
The 4-Item Structure
01
Objective: Observation of restless movements (pacing, foot tapping, rocking).
02
Subjective (Awareness): Patient reporting inner restlessness or urge to move.
03
Subjective (Distress): Patient reporting how distressing the urge to move is.
04
Global Clinical Assessment: An overall rating based on all above items.
Scoring Interpretation
Global Score 0
Absent (No Akathisia)
Global Score 1
Questionable/Pseudoakathisia
Global Score 2
Mild Akathisia (Diagnostic Cutoff)
Global Score 3
Moderate Akathisia
Global Score 4
Marked Akathisia
Global Score 5
Severe Akathisia
Section 3
Pearls/Pitfalls
The Global Assessment Rule
The Global Clinical Assessment is the most important item. A diagnosis of "clinical akathisia" is usually confirmed only if the Global score is 2 or higher.
Diagnostic Pearls
Observe the patient while standing and sitting; akathisia often worsens during static postures.
Always ask about "inner restlessness"—objective pacing may be absent in mild cases.
Consider "Pseudoakathisia" if movements are seen but the patient denies any inner urge to move.
Section 4
Next Steps
Clinical Actions
01
Global Score ≤ 1: Continue monitoring; consider non-pharmacological comfort measures.
02
Global Score ≥ 2: Evaluate for antipsychotic dose reduction or switch to a lower-potency D2 agent.
03
Pharmacotherapy: If dose reduction is not feasible, consider Propranolol (20-120mg/day) as first-line treatment.
04
Review: Re-assess in 48-72 hours after treatment initiation.
Section 5
Evidence Appraisal
Primary Reference
A rating scale for drug-induced akathisia
Barnes TR • British Journal of Psychiatry. 1989;154(5):672-6. The original publication establishing the BARS as the standard for clinical trials and practice.
